Vividion Therapeutics IPO

Vividion Therapeutics is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets.

Register for Details

For more details on financing and valuation of private companies similar to Vividion Therapeutics before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Vividion Therapeutics

To invest in Vividion Therapeutics pre-IPO

Can you invest in Vividion Therapeutics pre-IPO?

You can no longer invest in Vividion Therapeutics with Forge. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Vividion Therapeutics before it goes public?

You can no longer sell shares of Vividion Therapeutics on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Vividion Therapeutics shares?

Forge can no longer determine the value of Vividion Therapeutics shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Vividion Therapeutics a publicly traded company?

Vividion Therapeutics became a public company following its M&A on 08/05/2021 and is now a publicly traded company.

To learn more about Vividion Therapeutics potential IPO

Will Vividion Therapeutics go IPO?

Vividion Therapeutics became a public company following its M&A on 08/05/2021.

What is Vividion Therapeutics’ IPO price?

The IPO price of Vividion Therapeutics is not currently available.

When was Vividion Therapeutics founded?

Vividion Therapeutics was founded in 2013.

What is Vividion Therapeutics funding to date?

Vividion Therapeutics has raised $267.82MM to date.

Vividion Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
02/24/2021 Series C $135MM $xx.xx $600.09MM Acuta Capital, Arch Venture Partners, Avoro Capital Advisors, Blackrock, Boxer Capital, Bvf Partners, Casdin Capital, Driehaus Capital Management, Logos Capital, Mubadala Capital, Nextech Invest, Ra Capital Management, Softbank, Surveyor Capital, T. Rowe Price Associates, Versant Ventures, Woodline Partners
Price per Share
$xx.xx
Shares Outstanding
64,285,721
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acuta Capital, Arch Venture Partners, Avoro Capital Advisors, Blackrock, Boxer Capital, Bvf Partners, Casdin Capital, Driehaus Capital Management, Logos Capital, Mubadala Capital, Nextech Invest, Ra Capital Management, Softbank, Surveyor Capital, T. Rowe Price Associates, Versant Ventures, Woodline Partners
04/30/2019 Series B $82MM $xx.xx $304.43MM Alexandria Venture Investments, Altitude Life Science Ventures, Arch, Bvf Partners, Cardinal, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Ventures, Trinitas Capital, Versant
Price per Share
$xx.xx
Shares Outstanding
57,543,868
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Altitude Life Science Ventures, Arch, Bvf Partners, Cardinal, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Ventures, Trinitas Capital, Versant
02/02/2017 Series A-3 $5.9MM $xx.xx $118.29MM Arch Venture Partners, Cardinal Partners, Versant Venture
Price per Share
$xx.xx
Shares Outstanding
6,550,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Cardinal Partners, Versant Venture
02/02/2017 Series A-2 $40.4MM $xx.xx $118.29MM Arch Venture Partners, Cardinal Partners, Versant Venture
Price per Share
$xx.xx
Shares Outstanding
67,333,334
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Cardinal Partners, Versant Venture
03/31/2016 Series A $4.53MM $xx.xx $11.32MM Cardinal Partners
Price per Share
$xx.xx
Shares Outstanding
18,118,465
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cardinal Partners
Updated on: Dec 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.